Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo

S. Korsgaard, Daniel Casey, N. E. Damgaard Pedersen, A. Jørgensen, J. Gerlach

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Sixteen out of 19 patients suffering from chronic anergic schizophrenia completed a placebo-controlled crossover study with lysine-8-vasopressin (LVP), following a schedule of 1 week of placebo, 3 weeks of LVP, starting with 22.5 IU/day, gradually increased to 67.5 IU/day, and finally 4 weeks of placebo. The psychia state was evaluated with the Brief Psychiatric Rating Scale (BPRS), during weekly live interviews, and following videotaped BPRS interviews at the beginning and end of the LVP period, and at the end of the final placebo period. Symptoms of parkinsonism and tardive dyskinesia were also videotaped during a standardized examination at the same intervals. The videotapes were subsequently randomized and evaluated blindly. The results of the live interviews showed a significant (P

Original languageEnglish (US)
Pages (from-to)379-382
Number of pages4
JournalPsychopharmacology
Volume74
Issue number4
DOIs
StatePublished - Sep 1981

Fingerprint

Lypressin
Vasopressins
Cross-Over Studies
Schizophrenia
Placebos
Brief Psychiatric Rating Scale
Interviews
Videotape Recording
Parkinsonian Disorders
Appointments and Schedules

Keywords

  • Anergic schizophrenia
  • Lysine-8-vasopressin
  • Vasopressin
  • Video technique for blind evaluation

ASJC Scopus subject areas

  • Pharmacology

Cite this

Korsgaard, S., Casey, D., Damgaard Pedersen, N. E., Jørgensen, A., & Gerlach, J. (1981). Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo. Psychopharmacology, 74(4), 379-382. https://doi.org/10.1007/BF00432752

Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo. / Korsgaard, S.; Casey, Daniel; Damgaard Pedersen, N. E.; Jørgensen, A.; Gerlach, J.

In: Psychopharmacology, Vol. 74, No. 4, 09.1981, p. 379-382.

Research output: Contribution to journalArticle

Korsgaard, S, Casey, D, Damgaard Pedersen, NE, Jørgensen, A & Gerlach, J 1981, 'Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo', Psychopharmacology, vol. 74, no. 4, pp. 379-382. https://doi.org/10.1007/BF00432752
Korsgaard, S. ; Casey, Daniel ; Damgaard Pedersen, N. E. ; Jørgensen, A. ; Gerlach, J. / Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo. In: Psychopharmacology. 1981 ; Vol. 74, No. 4. pp. 379-382.
@article{d2428d393b8c4ae6ab4f83d674811143,
title = "Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo",
abstract = "Sixteen out of 19 patients suffering from chronic anergic schizophrenia completed a placebo-controlled crossover study with lysine-8-vasopressin (LVP), following a schedule of 1 week of placebo, 3 weeks of LVP, starting with 22.5 IU/day, gradually increased to 67.5 IU/day, and finally 4 weeks of placebo. The psychia state was evaluated with the Brief Psychiatric Rating Scale (BPRS), during weekly live interviews, and following videotaped BPRS interviews at the beginning and end of the LVP period, and at the end of the final placebo period. Symptoms of parkinsonism and tardive dyskinesia were also videotaped during a standardized examination at the same intervals. The videotapes were subsequently randomized and evaluated blindly. The results of the live interviews showed a significant (P",
keywords = "Anergic schizophrenia, Lysine-8-vasopressin, Vasopressin, Video technique for blind evaluation",
author = "S. Korsgaard and Daniel Casey and {Damgaard Pedersen}, {N. E.} and A. J{\o}rgensen and J. Gerlach",
year = "1981",
month = "9",
doi = "10.1007/BF00432752",
language = "English (US)",
volume = "74",
pages = "379--382",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - Vasopressin in anergic schizophrenia - A cross-over study with lysine-8-vasopressin and placebo

AU - Korsgaard, S.

AU - Casey, Daniel

AU - Damgaard Pedersen, N. E.

AU - Jørgensen, A.

AU - Gerlach, J.

PY - 1981/9

Y1 - 1981/9

N2 - Sixteen out of 19 patients suffering from chronic anergic schizophrenia completed a placebo-controlled crossover study with lysine-8-vasopressin (LVP), following a schedule of 1 week of placebo, 3 weeks of LVP, starting with 22.5 IU/day, gradually increased to 67.5 IU/day, and finally 4 weeks of placebo. The psychia state was evaluated with the Brief Psychiatric Rating Scale (BPRS), during weekly live interviews, and following videotaped BPRS interviews at the beginning and end of the LVP period, and at the end of the final placebo period. Symptoms of parkinsonism and tardive dyskinesia were also videotaped during a standardized examination at the same intervals. The videotapes were subsequently randomized and evaluated blindly. The results of the live interviews showed a significant (P

AB - Sixteen out of 19 patients suffering from chronic anergic schizophrenia completed a placebo-controlled crossover study with lysine-8-vasopressin (LVP), following a schedule of 1 week of placebo, 3 weeks of LVP, starting with 22.5 IU/day, gradually increased to 67.5 IU/day, and finally 4 weeks of placebo. The psychia state was evaluated with the Brief Psychiatric Rating Scale (BPRS), during weekly live interviews, and following videotaped BPRS interviews at the beginning and end of the LVP period, and at the end of the final placebo period. Symptoms of parkinsonism and tardive dyskinesia were also videotaped during a standardized examination at the same intervals. The videotapes were subsequently randomized and evaluated blindly. The results of the live interviews showed a significant (P

KW - Anergic schizophrenia

KW - Lysine-8-vasopressin

KW - Vasopressin

KW - Video technique for blind evaluation

UR - http://www.scopus.com/inward/record.url?scp=0019388069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019388069&partnerID=8YFLogxK

U2 - 10.1007/BF00432752

DO - 10.1007/BF00432752

M3 - Article

AN - SCOPUS:0019388069

VL - 74

SP - 379

EP - 382

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -